These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32013198)

  • 1. Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine.
    Hilimire TA; Nogales A; Chiem K; Ortego J; Martinez-Sobrido L
    Pathogens; 2020 Jan; 9(2):. PubMed ID: 32013198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine.
    Nogales A; Steel J; Liu WC; Lowen AC; Rodriguez L; Chiem K; Cox A; García-Sastre A; Albrecht RA; Dewhurst S; Martínez-Sobrido L
    Microbiol Spectr; 2022 Jun; 10(3):e0007822. PubMed ID: 35583364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus.
    Smith A; Rodriguez L; El Ghouayel M; Nogales A; Chamberlain JM; Sortino K; Reilly E; Feng C; Topham DJ; Martínez-Sobrido L; Dewhurst S
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31748399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines.
    White CL; Chiem K; Perez DR; Santos J; Cardenas Garcia S; Nogales A; Martínez-Sobrido L
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34208979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups.
    Bonifacio JPPL; Williams N; Garnier L; Hugues S; Schmolke M; Mazel-Sanchez B
    J Virol; 2022 Oct; 96(20):e0087122. PubMed ID: 36190240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bivalent Live-Attenuated Vaccine for the Prevention of Equine Influenza Virus.
    Blanco-Lobo P; Rodriguez L; Reedy S; Oladunni FS; Nogales A; Murcia PR; Chambers TM; Martinez-Sobrido L
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31614538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A live-attenuated influenza vaccine for H3N2 canine influenza virus.
    Rodriguez L; Nogales A; Reilly EC; Topham DJ; Murcia PR; Parrish CR; Martinez Sobrido L
    Virology; 2017 Apr; 504():96-106. PubMed ID: 28167384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
    Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
    Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay of PA-X and NS1 Proteins in Replication and Pathogenesis of a Temperature-Sensitive 2009 Pandemic H1N1 Influenza A Virus.
    Nogales A; Rodriguez L; DeDiego ML; Topham DJ; Martínez-Sobrido L
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28637750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Study of the Temperature Sensitive, Cold Adapted and Attenuated Mutations Present in the Master Donor Viruses of the Two Commercial Human Live Attenuated Influenza Vaccines.
    Rodriguez L; Blanco-Lobo P; Reilly EC; Maehigashi T; Nogales A; Smith A; Topham DJ; Dewhurst S; Kim B; Martínez-Sobrido L
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31658679
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Hughes HR; Brockmeier SL; Loving CL
    Front Immunol; 2018; 9():2255. PubMed ID: 30337924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge.
    Isakova-Sivak I; Matyushenko V; Kotomina T; Kiseleva I; Krutikova E; Donina S; Rekstin A; Larionova N; Mezhenskaya D; Sivak K; Muzhikyan A; Katelnikova A; Rudenko L
    Vaccines (Basel); 2019 Jul; 7(3):. PubMed ID: 31288422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live Attenuated Influenza H7N3 Vaccine is Safe, Immunogenic and Confers Protection in Animal Models.
    Rekstin A; Desheva Y; Kiseleva I; Ross T; Swayne D; Rudenko L
    Open Microbiol J; 2014; 8():154-62. PubMed ID: 25685247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Truncation of NS1 Protein Enhances T Cell-Mediated Cross-Protection of a Live Attenuated Influenza Vaccine Virus Expressing Wild-Type Nucleoprotein.
    Prokopenko P; Matyushenko V; Rak A; Stepanova E; Chistyakova A; Goshina A; Kudryavtsev I; Rudenko L; Isakova-Sivak I
    Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Innate Immune Responses by the Influenza A NS1 and PA-X Proteins.
    Nogales A; Martinez-Sobrido L; Topham DJ; DeDiego ML
    Viruses; 2018 Dec; 10(12):. PubMed ID: 30545063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterosubtypic protection against avian influenza virus by live attenuated and chimeric norovirus P-particle-M2e vaccines in chickens.
    Ghorbani A; Ngunjiri JM; Xia M; Elaish M; Jang H; Mahesh KC; Abundo MC; Jiang X; Lee CW
    Vaccine; 2019 Feb; 37(10):1356-1364. PubMed ID: 30691981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an Alternative Modified Live Influenza B Virus Vaccine.
    Santos JJS; Finch C; Sutton T; Obadan A; Aguirre I; Wan Z; Lopez D; Geiger G; Gonzalez-Reiche AS; Ferreri L; Perez DR
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
    Heldens J; Hulskotte E; Voeten T; Breedveld B; Verweij P; van Duijnhoven W; Rudenko L; van Damme P; van den Bosch H
    Vaccine; 2014 Sep; 32(39):5118-24. PubMed ID: 24858566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs.
    Hughes HR; Vincent AL; Brockmeier SL; Gauger PC; Pena L; Santos J; Braucher DR; Perez DR; Loving CL
    Clin Vaccine Immunol; 2015 Oct; 22(10):1109-20. PubMed ID: 26291090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.